Table 1 Characteristics of the study population at baselinea
From: Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
Characteristics | No TDF-toxicity risk N = 4′360 | TDF-toxicity risk N = 652 | P |
|---|---|---|---|
Male sex (%) | 3194 (73.3) | 451 (69.2) | 0.03 |
Median age in years (IQR) | 48 (40–54) | 56 (50–62) | < 0.001 |
African origin (%) | 742 (17.0) | 47 (7.2) | < 0.001 |
High-level education (%) | 1471 (33.7) | 181 (27.8) | 0.01 |
Transmission group (%) | < 0.001 | ||
MSM | 2071 (48.7) | 270 (42.4) | |
PWID | 396 (9.3) | 108 (17.0) | |
other | 1789 (42.0) | 259 (40.7) | |
Median CD4 count in cells/μL (IQR) | 640 (486–828) | 615 (443–826) | 0.01 |
Median CD4 nadir in cells/μL (IQR) | 226 (122–334) | 171 (75–273) | < 0.001 |
Type of center (%) | 0.44 | ||
Tertiary care center | 2256 (51.7) | 348 (53.4) | |
Other | 2104 (48.3) | 304 (46.6) | |
Chronic HBV infection (%) | 291 (7.1) | 47 (7.5) | 0.71 |
Chronic HCV infection (%) | 509 (11.9) | 115 (18.0) | < 0.001 |
History of CV disease (%) | 293 (6.7) | 95 (14.6) | < 0.001 |
Diabetes (%) | 245 (5.6) | 77 (11.8) | < 0.001 |
Arterial hypertension (%) | 2264 (51.9) | 405 (62.1) | < 0.001 |
Dyslipidemia (%) | 1′864 (42.8) | 345 (52.9) | < 0.001 |
Median eGFR in mL/min (IQR) | 93.8 (80.6–106.3) | 73.0 (56.3–95.5) | < 0.001 |
eGFR category (%) | < 0.001 | ||
> 90 mL/min | 2390 (57.3) | 198 (30.9) | |
60–90 mL/min | 1782 (42.7) | 200 (31.2) | |
< 60 mL/min | 0 | 243 (37.9) | |
Proteinuria (%) [n = 3102] | < 0.001 | ||
< 15 mg/mmol | 1920 (72.5) | 139 (30.6) | |
15–50 mg/mmol | 727 (27.5) | 162 (35.6) | |
> 50 mg/mmol | 0 | 154 (33.9) | |
Osteoporosis (%) | n.a. | ||
T-score ≤ −2.5 [n = 1624] | 0 | 273 (41.9) | |
Fragility fracture | 0 | 77 (11.8) | |
Combined | 0 | 325 (49.9) | |
PI-based ART (%) | 994 (22.8) | 184 (28.2) | 0.01 |
NNRTI-based single-pill regimen (%) | 1755 (40.3) | 223 (34.2) | 0.01 |